| Literature DB >> 25879579 |
Julia Michalow1,2, Lumbwe Chola3,4, Shelley McGee5,6, Aviva Tugendhaft7,8, Robert Pattinson9, Kate Kerber10, Karen Hofman11,12.
Abstract
BACKGROUND: The time of labor, birth and the first days of life are the most vulnerable period for mothers and children. Despite significant global advocacy, there is insufficient understanding of the investment required to save additional lives. In particular, stillbirths have been neglected. Over 20 000 stillbirths are recorded annually in South Africa, many of which could be averted. This analysis examines available South Africa specific stillbirth data and evaluates the impact and cost-effectiveness of 13 interventions acknowledged to prevent stillbirths and maternal and newborn mortality.Entities:
Mesh:
Year: 2015 PMID: 25879579 PMCID: PMC4337184 DOI: 10.1186/s12884-015-0456-9
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Causes of third trimester stillbirth in South Africa
|
|
|
|
|---|---|---|
| Intrapartum asphyxia | 28.9 | 4.6 |
| Antepartum hemorrhage | 26.9 | 9.1 |
| Unexplained intrauterine death | 15.7 | 47.9 |
| Hypertensive disorders | 10.1 | 19.1 |
| Spontaneous preterm labor | 7.2 | 4.2 |
| Fetal abnormality | 4.4 | 2.3 |
| Infections | 2.3 | 3.9 |
| Intrauterine growth retardation | 1.3 | 2.9 |
| Maternal disease | 1.2 | 3.6 |
| Miscellaneous | 0.9 | 1.3 |
| No obstetric cause/Not applicable | 0.6 | 0.6 |
| Trauma | 0.5 | 0.4 |
| Total | 100 | 100 |
Source: [6].
Figure 1Causes of newborn, child and maternal deaths in South Africa used in the LiST model. Source: Adapted from Medical Research Council burden of disease estimates in 2010.
Effect and affected fraction estimates for interventions to reduce stillbirths and maternal and neonatal deaths
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| ||||||
| Syphilis detection and treatment | 0.82 for antepartum stillbirths* | 0.21* | Minimal effect | - | 0.03 for sepsis | 1 |
| Hypertensive disease case management | 0.20 for antepartum and intrapartum stillbirths | 1 | 0.59 for hypertensive disease | 1* | Effect calculated as part of BEmOC and CEmOC | |
| Diabetes case management | 0.10 for antepartum and intrapartum stillbirths* | 0.106* | Unknown effect | - | Unknown effect | - |
| MgSO4 Management of pre-eclampsia | 0.20 for antepartum and intrapartum stillbirths* | 0.213* | 0.59 for hypertensive disease* | 1* | Unknown effect | - |
| Fetal growth restriction detection and management | 0.20 for antepartum and intrapartum stillbirths* | 0.202* | Unknown effect | - | Unknown effect | - |
| Labor and delivery management: Essential obstetric care | 0.23 for intrapartum stillbirths | 1* | 0.10 for sepsis | 1* | 0.25 for asphyxia*; 0.10 for prematurity*; 0.25 for sepsis; 0.36 for tetanus | 1* |
| Labor and delivery management: Basic emergency obstetric care (BEmOC) | 0.45 for intrapartum stillbirths | 1* | 0.08 for obstructed labor; 0.20 for antepartum hemorrhage*; 0.65 for postpartum hemorrhage; 0.50 for sepsis | 1* | 0.40 for asphyxia*; 0.10 for prematurity*; 0.25 for sepsis; 0.36 for tetanus | 1* |
| Labor and delivery management: Comprehensive emergency obstetric care (CEmOC) | 0.75 for intrapartum stillbirths | 1* | 0.99 for obstructed labor; 0.80 for antepartum hemorrhage*; 0.95 for postpartum hemorrhage; 0.99 for hypertensive disease of pregnancy; 0.70 for sepsis | 1* | 0.80 for asphyxia*; 0.10 for prematurity*; 0.25 for sepsis; 0.36 for tetanus | 1* |
| Induction of labor for pregnancies lasting 41+ weeks (CEmOC only) | 0.69 for antepartum and intrapartum stillbirths* | 0.036* | No effect | - | Unknown effect | - |
|
| ||||||
| Early detection and treatment of HIV in pregnant women | Unknown effect | - | 0.90 for other indirect causes | 0.8 | Unknown effect | - |
| Tetanus toxoid immunization during pregnancy | No effect | - | 0.98* | 0.005* | 0.94 for tetanus* | 1* |
| Antibiotics for preterm premature rupture of membranes | Unknown effect | - | 0.26 for sepsis | 0.1 | 0.12 for prematurity*; 0.08 for sepsis | 1 for both |
| Antenatal corticosteroids for preterm labor | No effect | - | No effect | - | 0.53 for prematurity* | 1 |
| Active management of the third stage of labor | No effect | - | 0.27 for postpartum hemorrhage | 1* | No effect | - |
| Neonatal resuscitation | No effect | - | No effect | - | 0.3 for asphyxia*; 0.1 for prematurity* | 1 for both* |
AF = Affected fraction; *Default LiST value in Spectrum V5.04. Sources: Adapted from Bhutta [31,32,36].
Baseline coverage estimates for interventions to reduce stillbirths and maternal and neonatal deaths
|
|
|
|---|---|
|
| |
| Syphilis detection and treatment | 92 |
| Hypertensive disease case management | 40 |
| Diabetes case management | 10 |
| MgSO4 Management of pre-eclampsia | 75 |
| Fetal growth restriction detection and management | 10 |
| Labor and delivery management | |
| Essential care | 22* |
| Basic emergency obstetric care | 13* |
| Comprehensive emergency obstetric care | 53* |
| Induction of labor for pregnancies lasting 41+ weeks | 10* |
|
| |
| Early detection and treatment of HIV in pregnant women | 40 |
| Tetanus toxoid immunization during pregnancy | 77* |
| Antibiotics for preterm premature rupture of membranes | 25 |
| Antenatal corticosteroids for preterm labor | 20 |
| Active management of the third stage of labor | 80 |
| Neonatal resuscitation | 40* |
*Default LiST value in Spectrum V5.04. Source: Consultation with expert South African panel.
Figure 2Stillbirth rates in South Africa (2000 to 2013). Sources: South African Health Review 2010 [3] and 2012/13 [46]; and Saving Babies reports 2000 – 2014 [6,18-23].
National distribution of births and stillbirths by level of facility (2012 and 2013)
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| Total births | 229 933 | 654 115 | 386 334 | 69 470 | 72 503 | 1 412 355 |
| Proportion of births (%) | 16.3 | 46.3 | 27.4 | 4.9 | 5.1 | 100 |
| SBR > 500 g | 8.4 | 20.2 | 30.2 | 39.2 | 42.9 | 23.1 |
| SBR > 1 000 g | 6.2 | 16.4 | 22.6 | 28.8 | 27.9 | 17.6 |
| Proportion of stillbirths (%) | 5.9 | 40.5 | 35.7 | 8.3 | 9.5 | 100 |
CHC – Community Health Centre; DH – District Hospital; RH – Regional Hospital; PT – Provincial Tertiary Hospital; NC – National Central Hospital; SBR – stillbirth rate per 1 000 births. Source: [6].
Figure 3Number of lives saved in 2030 with full intervention coverage and 70% family planning coverage.
Projected incremental costs and effects in 2030 with family planning at 70%
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
|
| ||||||
| Syphilis detection and treatment | 160 | - | 0 | 106 550 | 9 600 | 11 |
| Hypertensive disease case management | 460 | 150 | - | 35 040 | 31 650 | 1 |
| Diabetes case management | 180 | - | - | 8 194 520 | 10 800 | 759 |
| MgSO4 Management of pre-eclampsia | 450 | 70 | - | 5 492 600 | 28 890 | 190 |
| Fetal growth restriction detection and management | 690 | - | - | 2 876 410 | 41 400 | 69 |
| Labor and delivery management | 3 050 | 400 | 1 540 | 19 447 320 | 286 200 | 68 |
| Induction of labor for pregnancies lasting 41+ weeks | 390 | - | - | 2 436 610 | 23 400 | 104 |
|
| ||||||
| Early detection and treatment of HIV | - | 610 | - | 10 930 280 | 16 470 | 664 |
| Tetanus toxoid immunization | - | 2 | 50 | 614 240 | 3 054 | 201 |
| Antibiotics for PPROM | - | 20 | 470 | 769 780 | 28 740 | 27 |
| Antenatal corticosteroids | - | - | 2 030 | 4 527 270 | 121 800 | 37 |
| Active management of the third stage of labor | - | 80 | - | 1 547 670 | 2 160 | 717 |
| Neonatal resuscitation | - | - | 760 | 81 670 | 45 600 | 2 |
|
|
|
|
|
|
|
|
US$ = United States Dollars; numbers rounded to nearest 10 to indicate uncertainty.
Projected incremental costs and effects in 2030 for each family planning scenario
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| ||||||
| Syphilis detection and treatment | 160 | 106 550 | 120 | −2 544 770 | 90 | −4 794 400 |
| Hypertensive disease case management | 610 | 35 040 | 470 | 21 240 | 360 | 9 520 |
| Diabetes case management | 180 | 8 194 520 | 140 | 7 932 270 | 110 | 7 694 400 |
| MgSO4 Management of pre-eclampsia | 520 | 5 492 600 | 410 | −917 110 | 310 | −6 355 730 |
| Fetal growth restriction detection and management | 690 | 2 876 410 | 530 | 2 784 350 | 400 | 2 700 860 |
| Labor and delivery management | 4990 | 19 447 320 | 3 870 | −41 901 940 | 2 920 | −93 956 580 |
| Induction of labor for pregnancies lasting 41+ weeks | 390 | 2 436 610 | 300 | 1 856 720 | 230 | 1 364 690 |
|
| ||||||
| Early detection and treatment of HIV | 610 | 10 930 280 | 470 | 2 462 090 | 360 | −4 705 650 |
| Tetanus toxoid immunization | 52 | 614 240 | 40 | −193 090 | 30 | −878 110 |
| Antibiotics for PPROM | 490 | 769 780 | 380 | 542 300 | 280 | 349 290 |
| Antenatal corticosteroids | 2030 | 4 527 270 | 1 580 | 3 269 430 | 1 190 | 2 202 160 |
| Active management of the third stage of labor | 80 | 1 547 670 | 70 | 25 240 | 50 | −1 266 540 |
| Neonatal resuscitation | 760 | 81 670 | 590 | 51 850 | 440 | 26 330 |
|
|
|
|
|
|
|
|
US$ = United States Dollar; numbers rounded to nearest 10 to indicate uncertainty.
Summary of projected total and incremental costs in 2030 for each family planning scenario
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Intervention costs | 383 238 300 | 57 059 960 | 299 566 910 | −26 611 430 | 228 568 580 | −97 609 750 |
| Family planning costs | 166 992 040 | 27 368 480 | 180 953 420 | 41 329 860 | 192 830 510 | 53 206 950 |
| Overall cost | 550 230 340 | 84 428 440 | 480 520 330 | 14 718 430 | 421 399 090 | −44 402 800 |
| Overall cost per capita | 10.2 | 1.6 | 8.9 | 0.3 | 7.8 | −0.8 |
US$ = United States Dollars; numbers rounded to nearest 10 to indicate uncertainty.